Oncology Billing— Chemotherapy, Drug Supply, Prior Auth & Every High-Value Claim Paid
Oncology billing is the highest-stakes, highest-value billing in all of medicine — chemotherapy administration codes with strict hierarchy rules, drug supply billing worth thousands per infusion session, prior authorization on every treatment cycle, and a payer environment that scrutinizes every oncology claim with extraordinary intensity. Netix handles every layer so your oncologists focus on patients while we make sure every treatment session gets paid in full.
Chemotherapy administration hierarchy applied correctly
Drug supply J-code billing on every infusion
Prior auth management for every treatment cycle
THE PROBLEM
Why Oncology Practices Lose More Per Claim Than Any Other Specialty
Oncology billing errors are uniquely expensive — because oncology claims are uniquely valuable. A chemotherapy administration hierarchy error, a missed drug supply J-code, or a prior authorization failure on a treatment cycle does not cost $15. It costs thousands per session — and on a busy oncology practice treating patients multiple times per week, systematic errors compound into catastrophic monthly revenue loss. Here is where the losses happen most consistently
Chemotherapy administration hierarchy rules are the most complex infusion billing rules in medicine.
When multiple infusion services are provided in a single encounter — chemotherapy, hydration, anti-nausea pre-medication, growth factor injection — the hierarchy of codes determines which service is primary, which are sequential, and which are concurrent. The primary service determines whether a chemotherapy or non-chemotherapy administration code is used, and getting the hierarchy wrong means either billing non-chemotherapy codes for a chemotherapy encounter (significant underpayment) or billing the wrong primary service (denial or audit). Most oncology practices either apply the hierarchy incorrectly or default to a simplified billing approach that leaves significant administration revenue unclaimed.
Drug supply billing is the highest-value line item in oncology — and the most commonly incomplete.
Every chemotherapy drug, every biologic, every supportive care drug administered in the office or infusion suite has a separately billable J-code or HCPCS code — and the billing must reflect the exact drug, exact dosage, and exact units administered. A 650mg dose of carboplatin, a 400mg dose of rituximab, a specific vial size of filgrastim — each billed at the correct per-unit amount. Missing J-codes, wrong per-unit calculations, or vague drug billing without specific HCPCS codes means thousands of dollars in drug reimbursement lost per session.
Prior authorization on every treatment cycle is the most resource-intensive compliance requirement in oncology.
Every chemotherapy regimen, every biologic therapy, every targeted agent requires prior authorization — and the auth for oncology is more documentation-intensive than any other specialty. Pathology reports, staging documentation, performance status, prior treatment failure evidence, and NCCN guideline alignment documentation must all be prepared and submitted. A missing auth or an auth obtained for the wrong regimen means a complete denial on a claim worth tens of thousands.
Hydration and pre-medication billing is routinely bundled when it should not be.
Hydration infusion (96360, 96361) and non-chemotherapy drug infusion for pre-medications (anti-nausea, corticosteroids, antihistamines) are separately billable alongside chemotherapy — but only when they meet the requirements for separate billing (administered before or after chemotherapy for a clinically independent reason, for at least 31 minutes). Most oncology practices either miss hydration billing entirely or bundle it incorrectly.
Evaluation and management visits in oncology are systematically undercoded.
Oncology E&M visits involve extraordinary clinical complexity — cancer diagnosis management, treatment toxicity monitoring, performance status assessment, and treatment decision making of the highest risk level. Under the 2021 MDM framework, almost every oncology E&M visit supports 99215. Most oncology practices bill 99213 or 99214 as a default — and the undercoding compounds across every patient visit every day.
Supportive care drug billing is incomplete on most claims.
Growth factors (filgrastim, pegfilgrastim), anti-nausea medications (ondansetron, aprepitant), and other supportive care drugs administered in the office have their own J-codes and must be billed with correct per-unit calculations. Missing supportive care drug billing on every chemotherapy day represents thousands in monthly lost revenue.
OUR ONCOLOGY BILLING SERVICES
What Netix Handles for Oncology Practices
Chemotherapy Administration Billing
Correct administration code hierarchy on every infusion encounter — primary chemotherapy infusion (96413 first hour, 96415 each additional hour), sequential infusion (96417), concurrent infusion (96416), push administration (96409, 96411), and intramuscular/subcutaneous chemotherapy (96401–96402) — with hierarchy rules applied correctly based on the specific drugs and administration sequence for each patient session.
Non-Chemotherapy Infusion & Injection Billing
Pre-medication hydration (96360, 96361), non-chemotherapy drug infusion for supportive medications (96365–96368), and injection administration (96372) — correctly separated from chemotherapy administration when meeting separate billing requirements, with concurrent vs sequential vs primary distinction applied correctly.
Drug Supply Billing — Chemotherapy
J-code and HCPCS billing for every chemotherapy drug administered — carboplatin (J9045), cisplatin (J9060), paclitaxel (J9265), docetaxel (J9171), doxorubicin (J9000), cyclophosphamide (J9070), gemcitabine (J9201), oxaliplatin (J9263) — with exact dose-based per-unit calculations, NDC number documentation where required, and payer-specific drug billing requirements.
Drug Supply Billing — Biologics & Targeted Agents
Rituximab (J9312), trastuzumab (J9355), bevacizumab (J9035), pembrolizumab (J9271), nivolumab (J9299), atezolizumab (J9022), and other biologic and targeted therapies — high-value drug billing with correct per-unit calculation, prior auth confirmation before administration, and NDC documentation.
Supportive Care Drug Billing
Filgrastim (J1440, J1441), pegfilgrastim (J2505), epoetin alfa (Q4081), darbepoetin (J0881), ondansetron (J2405), aprepitant (J0185), dexamethasone (J1100) — separately billable supportive care drugs coded with correct J-codes and per-unit calculations on every qualifying encounter.
Oral Oncology Drug Billing
Oral chemotherapy parity laws in applicable states, patient assistance program coordination, and correct billing for oral chemotherapy drugs dispensed through the practice where applicable.
Radiation Oncology Billing
Radiation treatment management (77427), external beam radiation (77385–77387), stereotactic radiosurgery (77371–77373), brachytherapy (77750–77790) — radiation billing separated correctly from medical oncology administration billing.
Oncology E&M Level Optimization
MDM-based E&M level review for oncology — cancer management visits involve high-risk medications, extensive diagnostic data review, and clinical decisions of extraordinary complexity. 99215 applies on virtually every oncology E&M under the 2021 MDM framework. Systematic undercoding at lower levels costs significantly across high-volume oncology practices.
Port and Catheter Billing
Port access (96522), catheter irrigation, and implanted venous access device management — separately billable services that most oncology practices either miss or bundle incorrectly into administration codes.
Prior Authorization Management
Chemotherapy regimen auth, biologic agent auth, targeted therapy auth, radiation treatment auth — with NCCN guideline documentation, pathology and staging documentation, performance status, and prior treatment failure evidence prepared for every submission. Step therapy documentation and medical necessity for second-line or later regimens managed with clinical oncology expertise.
Denial Management — Oncology Specific
Drug supply denials, administration hierarchy disputes, prior auth denials on high-value regimens, medical necessity challenges, and step therapy requirement denials — appealed with oncology-specific clinical documentation, pathology reports, and NCCN guideline alignment evidence.
CHEMOTHERAPY ADMINISTRATION HIERARCHY EXPLAINED
Chemotherapy Administration Hierarchy — The Rules That Determine Every Infusion Claim
The chemotherapy administration hierarchy is the most complex infusion billing framework in medicine — and the most financially consequential when misapplied.
The hierarchy concept:
When multiple infusion services are provided in a single encounter, one service is designated the primary service. The primary service determines the billing framework for the entire encounter — and getting it wrong means the entire claim is miscoded.
The hierarchy rules:
Step 1 — Is chemotherapy administered?
If yes — a chemotherapy administration code is the primary service regardless of what else is given. The encounter is a chemotherapy encounter.
Step 2 — Primary chemotherapy service:
96413: Chemotherapy, intravenous infusion, up to 1 hour (primary, first drug)
96415: Each additional hour (add-on)
96409: Chemotherapy push, single or initial substance
96401: Chemotherapy, subcutaneous or intramuscular
Step 3 — Sequential chemotherapy (different drug, same IV line, after primary):
96417: Each additional sequential infusion of a different therapeutic agent (add-on)
Step 4 — Concurrent chemotherapy (same IV line, same time as primary):
96416: Concurrent infusion (add-on) — significantly lower reimbursement than sequential
Step 5 — Non-chemotherapy drugs in the same encounter:
Pre-medications, anti-nausea drugs, and supportive medications billed as non-chemotherapy infusion (96365, 96366, 96367) or injection (96372) — only when administered as a separately identifiable service for at least 31 minutes and not directly related to the chemotherapy infusion itself.
Step 6 — Hydration:
96360 (initial 31 minutes), 96361 (each additional hour) — only separately billable when administered as an independent service, not as a vehicle for drug administration.
What goes wrong:
Billing non-chemotherapy infusion codes (96365–96368) as the primary service when chemotherapy was administered — underpayment because non-chemo codes pay less than chemo codes. Missing sequential infusion add-ons (96417) for each additional chemotherapy drug. Billing concurrent (96416) when sequential (96417) applies — lower reimbursement on a separately payable drug. Missing hydration billing when it qualifies as separate.
What we do:
Drug-by-drug, sequence-by-sequence administration code assignment on every infusion encounter — hierarchy verified against the infusion nursing notes before every claim.
DRUG BILLING IN ONCOLOGY
Oncology Drug Billing — J-Codes, Per-Unit Calculations & Thousands Per Session
Drug billing is the highest-value component of every oncology claim — and the most documentation-intensive.
The two-component rule:
Every drug administered in an oncology office or infusion suite has two separately billable components — the administration (what the nurse does) and the drug supply (what was administered). Both must be billed on every claim. Missing the drug J-code on a chemotherapy session means losing the largest revenue component of the entire claim.
Per-unit calculation:
J-codes are billed in units — and the units are drug-specific. Some J-codes bill per milligram, some per 10 milligrams, some per 100 milligrams, some per vial. Getting the per-unit calculation wrong means either underbilling (billing fewer units than administered) or overbilling (billing more units than administered — a compliance violation). The calculation must be based on the exact dose administered, documented in the nursing note.
NDC documentation:
Medicare and an increasing number of commercial payers require the National Drug Code (NDC) number alongside the J-code for drug billing — identifying the specific manufacturer, product, and package size. Missing NDC documentation is a common denial reason on oncology drug claims.
Waste billing:
When a single-dose vial is used and the remaining drug is discarded, the waste may be billable — the full vial amount billed with a JW modifier indicating the discarded portion. Missing waste billing on single-dose vials is consistently missed revenue on expensive oncology drugs.
What we handle:
J-code assignment for every drug administered, per-unit calculation based on documented dose, NDC number documentation, waste billing with JW modifier, and payer-specific drug billing requirements — on every drug on every claim.
ONCOLOGY CPT & HCPCS CODES WE KNOW COLD
Oncology CPT & HCPCS Codes — Handled by Specialists
| Code | Service | Common Issue |
|---|---|---|
| 96413 | Chemo IV infusion first hour | Non-chemo code billed as primary |
| 96415 | Chemo infusion add-on hour | Add-on hours missed |
| 96417 | Sequential chemo infusion | Concurrent code billed instead |
| 96416 | Concurrent chemo infusion | Sequential opportunity missed |
| 96409 | Chemo push single substance | Hierarchy misapplication |
| 96401 | Chemo subcutaneous/IM | Administration component missed |
| 96365 | Non-chemo IV infusion first hour | Primary when chemo given — underpayment |
| 96366 | Non-chemo IV add-on hour | Add-on hours missed |
| 96372 | Injection therapeutic | Drug supply J-code missed |
| 96360 | Hydration first 31 min | Separate billing criteria not met |
| 96361 | Hydration add-on hour | Bundling when not separately payable |
| J9045 | Carboplatin per 50mg | Per-unit calculation errors |
| J9265 | Paclitaxel per 30mg | NDC documentation missing |
| J9312 | Rituximab per 100mg | Per-unit underbilling |
| J9271 | Pembrolizumab per 1mg | High-value — unit calculation critical |
| J9299 | Nivolumab per 1mg | Auth required every cycle |
| J9035 | Bevacizumab per 10mg | Waste billing missed |
| J2505 | Pegfilgrastim per 6mg | Supportive care drug billing missed |
| J1440 | Filgrastim per 300mcg | Per-unit calculation errors |
| J2405 | Ondansetron per 1mg | Supportive care J-code missed |
| 77427 | Radiation treatment management | Per 5 fractions billing confusion |
| 99202–99215 | Office E&M visits | Systematic 99214 undercoding |
| G0463 | Hospital outpatient E&M | Facility billing distinction |
| 96522 | Port access | Missed alongside administration billing |
PRIOR AUTHORIZATION IN ONCOLOGY
Oncology Prior Authorization — The Most Documentation-Intensive Auth in Medicine
Prior authorization for oncology treatment is unlike authorization in any other specialty — the documentation requirements are extensive, the timelines are urgent (cancer treatment cannot wait weeks for a delayed auth), and the financial stakes of a failed auth are enormous.
What every oncology auth requires:
Pathology documentation:
- Tissue biopsy report confirming cancer diagnosis
- Molecular testing results (KRAS, EGFR, ALK, PD-L1, HER2, MSI status)
- Stage and grade documentation
Treatment justification:
- NCCN guideline category for the proposed regimen
- Line of therapy (first-line, second-line, subsequent)
- Prior treatment history and response/failure documentation
- Performance status (ECOG 0–4)
Regimen-specific requirements:
- Immunotherapy: PD-L1 testing results, MSI/MMR status
- Targeted therapy: molecular testing confirming target mutation
- Biosimilar vs reference product documentation
The timeline problem:
Cancer treatment auth cannot follow the standard 5–10 business day timeline that most commercial payer auth processes use. Urgent and expedited auth processes exist — but they require knowing which payer programs apply and how to access them. We manage the oncology authorization process with urgency protocols for every submission.
Peer-to-peer review:
When oncology auth is denied on initial submission — which happens regularly for second-line and later regimens — peer-to-peer review with the payer’s medical director is the most effective appeal pathway. We coordinate peer-to-peer reviews with your oncologists and prepare the clinical summary for every review.
What we do:
Complete documentation package assembly for every regimen auth, urgency protocol activation when treatment timing requires it, peer-to-peer coordination on denials, and auth renewal management across long treatment courses.
Who We Serve
Oncology Providers We Work With
Medical oncology practices
Chemotherapy administration, drug supply billing, and E&M optimization
Hematology/oncology practices
Malignant and benign hematology billing alongside oncology
Infusion center billing
High-volume infusion billing with correct hierarchy and drug supply capture
Radiation oncology practices
Treatment management billing, external beam and SRS coding
Gynecologic oncology
Surgical oncology billing alongside chemotherapy administration
Surgical oncology practices
Cancer surgery billing, lymph node dissection add-ons, and reconstruction coding
Pediatric oncology
Pediatric dosing J-code calculations, Medicaid oncology billing, and pediatric-specific protocol auth
Academic oncology programs
Clinical trial billing separation, teaching physician rules, and research billing compliance
RESULTS WE BUILD TOWARD
What Oncology Billing Looks Like When It Works
First-pass clean claim rate: 94%+
Days in AR: under 40 (oncology AR runs longer due to auth cycles and drug claim complexity — but should never exceed 50)
Drug supply capture: 100% — J-code on every drug on every claim
Administration hierarchy accuracy: 100% — pre-submission audit on every infusion encounter
Prior auth approval before treatment: 100% — no treatment without confirmed auth
Waste billing capture: JW modifier on every qualifying single-dose vial
Monthly report: revenue per oncologist, per drug category, per administration type, per payer — with drug cost vs drug reimbursement tracked
Numbers based on industry benchmarks — your practice-specific results reported monthly.
FAQ
Oncology Billing Questions
What is the chemotherapy administration hierarchy and why does it matter?
The hierarchy determines which administration code is primary when multiple infusion services are given in one session. If chemotherapy is administered, a chemotherapy code must be primary — billing non-chemotherapy codes as primary when chemo was given means significant underpayment. The hierarchy also determines which additional drugs are sequential vs concurrent — a distinction worth hundreds per session. The free audit includes a hierarchy review on recent infusion claims.
How do we ensure drug supply billing is complete on every claim?
Every drug administered must have a corresponding J-code or HCPCS code billed at the correct per-unit amount based on the dose administered. The most common error is missing J-codes entirely — submitting only administration codes without the drug supply. On a chemotherapy claim worth thousands in drug reimbursement, missing the J-codes loses the majority of the claim value.
Can you handle prior authorization for all our treatment regimens?
Yes — complete auth package assembly including pathology, molecular testing, NCCN guideline documentation, line of therapy, and prior treatment history for every regimen. Urgency protocols for time-sensitive treatment starts, peer-to-peer coordination on initial denials, and auth renewal management across extended treatment courses.
What is waste billing and are we doing it?
When a single-dose vial is partially used and the remainder is discarded, the full vial amount can be billed with modifier JW indicating the discarded portion. On expensive oncology drugs, waste billing represents meaningful additional revenue per session. Most oncology practices either do not bill waste or are unaware it is billable.
We administer biologics and immunotherapy. Is the billing different from chemotherapy?
Yes — biologic and immunotherapy drugs have their own J-codes (pembrolizumab J9271, nivolumab J9299, rituximab J9312) with per-unit calculations specific to each drug. The administration codes (96413–96417) apply the same hierarchy rules. Prior auth requirements are more intensive — PD-L1 testing, MSI status, and specific molecular testing results are required for most immunotherapy auths.
What makes oncology billing harder than any other specialty?
The chemotherapy administration hierarchy, drug supply billing with per-unit calculations and NDC documentation for drugs worth thousands per dose, prior authorization intensity with pathology and molecular testing documentation requirements, waste billing, radiation billing complexity, and the financial magnitude of every error — because oncology claims are the highest-value outpatient claims in medicine. A general biller applies infusion billing logic to oncology — that approach misses drug revenue and hierarchy accuracy on every treatment session.
Find Out What Your Oncology Practice Should Be Collecting Per Treatment Session
The free oncology billing audit reviews your administration hierarchy accuracy, drug supply J-code capture, prior auth process, waste billing, E&M distribution, and denial patterns — and shows you in plain numbers what every treatment session should be generating versus what it actually is.